You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
受厂房调查影响 强生本周新冠疫苗交付将大减86%
阿思达克 04-12 15:22
《CNBC》报道,据美国疾控中心数据,强生(JNJ.US)本周将大幅削减新冠疫苗供应,由上周的490万剂降至本周的70万剂,减幅为86%。公司正等候美国食品及药物管理局对Emergent BioSolutions营运巴尔的摩主要疫苗厂的调查。

该巴尔的摩厂房员工数周前错误把强生及阿斯利康的疫苗原料掉换,导致1,500万剂疫苗无法使用。美国总统拜登政府已指令强生负责该厂的新冠疫苗生产,并停止该厂房就阿斯利康疫苗的生产。白宫表示,当巴尔的摩厂房获准复产,强生每周可交付800万剂疫苗,并可如期於5月底前交付1亿剂。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account